Tag: Chronic gvhd

For myelofibrosis patients with intermediate- or high-risk disease, long-term treatment with Jakafi (ruxolitinib) has been shown to improve overall survival compared to conventional therapies. However, the exact duration of how long you can stay on Jakafi is highly dependent on the specific medical condition being treated and the patient's individual response.

Based on clinical trial data, the median time to first response for Rezurock (belumosudil) in treating chronic graft-versus-host disease (cGVHD) was 1.8 months. For many, the question of **how long does it take for Rezurock to work?** is crucial for managing expectations during this long-term treatment.